-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $250

Benzinga·01/20/2026 16:03:20
Listen to the news
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $245 to $250.